Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Noor A. M. Bakker"'
Autor:
Leonie Voorwerk, Olga I. Isaeva, Hugo M. Horlings, Sara Balduzzi, Maksim Chelushkin, Noor A. M. Bakker, Elisa Champanhet, Hannah Garner, Karolina Sikorska, Claudette E. Loo, Inge Kemper, Ingrid A. M. Mandjes, Michiel de Maaker, Jasper J. L. van Geel, Jorianne Boers, Maaike de Boer, Roberto Salgado, Marloes G. J. van Dongen, Gabe S. Sonke, Karin E. de Visser, Ton N. Schumacher, Christian U. Blank, Lodewyk F. A. Wessels, Agnes Jager, Vivianne C. G. Tjan-Heijnen, Carolien P. Schröder, Sabine C. Linn, Marleen Kok
Publikováno v:
Nature Cancer, 4, 535-549. Springer Nature
Nature Cancer, 4(4), 535-549. Nature Research
Nature Cancer, 4(4), 535-549. Nature Research
Invasive lobular breast cancer (ILC) is the second most common histological breast cancer subtype, but ILC-specific trials are lacking. Translational research revealed an immune-related ILC subset, and in mouse ILC models, synergy between immune chec
Autor:
Joost H van den Berg, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Marit M van Buuren, Henk Mallo, Matthias Karger, Joris A van der Hage, Loes M Pronk, Marnix H Geukes Foppen, Bastiaan Nuijen, Ton N Schumacher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Purpose Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.Experimental Ten patients were treated
Externí odkaz:
https://doaj.org/article/dcfa2791fafa4572a3dce6276ee8be68
Autor:
Maartje Van Ruiten, Nienke E. van Trommel, Ekaterina S. Jordanova, John B. A. G. Haanen, Ton N. Schumacher, Gemma G. Kenter, Jossie Rotman, Marc van Beurden, Noor A. M. Bakker, Sanne Samuels, Bastiaan Nuijen, Karin E. de Visser, Tanja D. de Gruijl, Jos H. Beijnen, Henry Zijlmans, Joost H. van den Berg
Publikováno v:
Bakker, N A M, Rotman, J, Van Beurden, M, Zijlmans, H J M A A, Van Ruiten, M, Samuels, S, Nuijen, B, Beijnen, J, De Visser, K, Haanen, J, Schumacher, T, De Gruijl, T D, Jordanova, E S, Kenter, G G, Van Den Berg, J H & Van Trommel, N E 2021, ' HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN) : A phase I/II clinical trial ', Journal for Immunotherapy of Cancer, vol. 9, no. 8, 002547 . https://doi.org/10.1136/jitc-2021-002547
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer, 9(8):002547. BioMed Central
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer, 9(8):002547. BioMed Central
Journal for Immunotherapy of Cancer
BackgroundUsual vulvar intraepithelial neoplasia (uVIN) is a premalignancy caused by persistent infection with high-risk types of human papillomavirus (HPV), mainly type 16. Even though different treatment modalities are available (eg, surgical excis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb52bf3c6adfbc91bc3923e54b6cf18
https://research.vumc.nl/en/publications/835225f1-3bfb-4c3a-80d9-30f8b85de4ca
https://research.vumc.nl/en/publications/835225f1-3bfb-4c3a-80d9-30f8b85de4ca
Autor:
Gabe S. Sonke, Ferry Lalezari, Leonie Voorwerk, John B. A. G. Haanen, SuFey Ong, T. Wiersma, Noor A. M. Bakker, Philip C. Schouten, Ton N. Schumacher, Harm van Tinteren, Inge Kemper, Karin E. de Visser, Nicola S. Russell, Hugo M. Horlings, Karolina Sikorska, Maarten Slagter, Marleen Kok, Sarah Warren, I.A.M. Mandjes, Erik van Werkhoven, Myriam Chalabi, Michiel de Maaker, Dennis Peters, Sofie Wilgenhof, Iris Nederlof, Sabine C. Linn, Suzanne Onderwater, Charlotte A.H. Lange, Roelof J.C. Kluin, Roberto Salgado, Koen Van de Vijver, Lodewyk F. A. Wessels, Steven L. C. Ketelaars, Christian U. Blank
Publikováno v:
Nature medicine, 25(6), 920-928. Nature Publishing Group
The efficacy of programmed cell death protein 1 (PD-1) blockade in metastatic triple-negative breast cancer ( TNBC ) is low1–5, highlighting a need for strategies that render the tumor microenvironment more sensitive to PD-1 blockade. Preclinical r
Autor:
Christian U. Blank, Sofie Wilgenhof, J.B.A.G. Haanen, Loes M. Pronk, Maartje W. Rohaan, J.H. van den Berg, B.A. van de Wiel, T.N. Schumacher, A. Sari, Ferry Lalezari, H. van Tinteren, Raquel Gomez-Eerland, H. Mallo, M. van Zon, Bastiaan Nuijen, J.V. van Thienen, M.H. Geukes Foppen, J. H. Beijnen, R. De Boer, Noor A. M. Bakker
Publikováno v:
Annals of Oncology. 30:v481-v482
Background Adoptive cell therapy (ACT) with T cell receptor (TCR) gene modified peripheral blood T cells creates large pools of tumor reactive T cells. Based on preclinical validation we have selected a high affinity MART-1-specific TCR for TCR gene
Autor:
Koen A. Marijt, Timo K. van den Berg, Arianne M. Brandsma, Matthijs Raaben, Raquel Gomez-Eerland, Ton N. Schumacher, Noor A. M. Bakker, Jacques Neefjes, Astrid Fauster, Thijn R. Brummelkamp, Mireille Toebes, Simone van der Schot, Jeanette H. W. Leusen, Joost H. van den Berg, Martijn Verdoes, Katka Franke, Hanke L. Matlung, Ferenc A. Scheeren, J. H. Marco Jansen, Meike Emma Willemijn Logtenberg, John B. A. G. Haanen
Publikováno v:
Nature medicine
Nature Medicine, 25, 4, pp. 612-619
Nature medicine, 25(4), 612-619. Nature Publishing Group
Nature Medicine, 25(4), 612
Nature Medicine
Nature Medicine, 25, 612-619
Nature Medicine, 25, 4, pp. 612-619
Nature medicine, 25(4), 612-619. Nature Publishing Group
Nature Medicine, 25(4), 612
Nature Medicine
Nature Medicine, 25, 612-619
Cancer cells are able to evade immune surveillance through the expression of inhibitory ligands that bind their cognate receptors on immune effector cells. Expression of Programmed Death-Ligand 1 (PD-L1) in tumor micro-environments is a major immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7424239d9777176a6df9b7f382570737
https://doi.org/10.1038/s41591-019-0356-z
https://doi.org/10.1038/s41591-019-0356-z
Autor:
Leonie Voorwerk, Olga S. Blomberg, L. Spagnuolo, M.S. van der Heijden, M. Duijst, Emile E. Voest, E. van Dyk, J. van Dorp, K.E. De Visser, Olga I. Isaeva, Marleen Kok, Myriam Chalabi, Hannah Garner, Lodewyk F. A. Wessels, Kelly Kersten, C. Klaver, Noor A. M. Bakker, L.R. Hoes, Willemijn S. M. E. Theelen
Publikováno v:
Annals of Oncology. 31:S1142
Autor:
Christian U. Blank, Hans van Thienen, Pia Kvistborg, Marnix Geukes, Joost H. van den Berg, Ton N. Schumacher, John B. A. G. Haanen, Maaike van Zon, Noor A. M. Bakker
Publikováno v:
Molecular Cancer Therapeutics. 14:PL01-03
Infusion of tumor-infiltrating T-lymphocytes was developed as treatment for metastatic melanoma by Dr. S. Rosenberg (Surgery Branch, NIH, Bethesda, MD, USA) in the late 90's of the past century. This therapy was based on the finding that melanomas of
Autor:
Marleen Kok, Michiel de Maaker, Christian U. Blank, Iris Nederlof, SuFey Ong, Koen Van de Vijver, Philip C. Schouten, Sofie Wilgenhof, Karin E. de Visser, John B. A. G. Haanen, Harm van Tinteren, Hugo M. Horlings, Ferry Lalezari, Gabe S. Sonke, Erik van Werkhoven, Inge Kemper, Suzanne Onderwater, T. Wiersma, I.A.M. Mandjes, Maarten Slagter, Roberto Salgado, Sarah Warren, Charlotte A.H. Lange, Ton N. Schumacher, Roelof J.C. Kluin, Leonie Voorwerk, Nicola S. Russell, Myriam Chalabi, Noor A. M. Bakker, Karolina Sikorska, Sabine C. Linn, Lodewyk F. A. Wessels, Steven L. C. Ketelaars, Dennis Peters
Publikováno v:
Nature Medicine. 25:1175-1175
In the version of this article originally published, there was an error in Fig. 3j. A label on the heatmap read "TGF-α signaling via NF-κB". It should have read "TNF-α signaling via NF-κB". The error has been corrected in the HTML and PDF version
Autor:
Ton N. Schumacher, John B. A. G. Haanen, Noor A. M. Bakker, Raquel Gomez-Eerland, Maartje W. Rohaan, Joost H. van den Berg, Bastiaan Nuijen, Renate de Boer, Maaike van Zon
Publikováno v:
Cancer Immunology Research. 7:B205-B205
Currently a TCR gene therapy trial to treat stage IV cutaneous and uveal melanoma patients is being conducted at the NKI. The TCR used for T-cell modification is specific for the HLA-A*0201 restricted MART-126-35 epitope, which is expressed on the ma